- Home
- MDGL vs IVZ Comparison
MDGL vs IVZ Comparison
Compare MDGL & IVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- IVZ
- Stock Information
- Founded
- MDGL 2011
- IVZ 1935
- Country
- MDGL United States
- IVZ United States
- Employees
- MDGL N/A
- IVZ N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- IVZ Investment Managers
- Sector
- MDGL Health Care
- IVZ Finance
- Exchange
- MDGL Nasdaq
- IVZ Nasdaq
- Market Cap
- MDGL 6.1B
- IVZ 7.0B
- IPO Year
- MDGL N/A
- IVZ 1995
- Fundamental
- Price
- MDGL $302.17
- IVZ $20.62
- Analyst Decision
- MDGL Strong Buy
- IVZ Hold
- Analyst Count
- MDGL 9
- IVZ 16
- Target Price
- MDGL $420.63
- IVZ $18.80
- AVG Volume (30 Days)
- MDGL 371.3K
- IVZ 9.0M
- Earning Date
- MDGL 08-05-2025
- IVZ 07-22-2025
- Dividend Yield
- MDGL N/A
- IVZ 4.08%
- EPS Growth
- MDGL N/A
- IVZ N/A
- EPS
- MDGL N/A
- IVZ 0.80
- Revenue
- MDGL $317,383,000.00
- IVZ $6,153,100,000.00
- Revenue This Year
- MDGL $286.67
- IVZ N/A
- Revenue Next Year
- MDGL $67.98
- IVZ $9.85
- P/E Ratio
- MDGL N/A
- IVZ $25.61
- Revenue Growth
- MDGL N/A
- IVZ 5.83
- 52 Week Low
- MDGL $200.63
- IVZ $11.60
- 52 Week High
- MDGL $377.46
- IVZ $21.85
- Technical
- Relative Strength Index (RSI)
- MDGL 48.85
- IVZ 68.03
- Support Level
- MDGL $286.44
- IVZ $20.00
- Resistance Level
- MDGL $312.05
- IVZ $21.85
- Average True Range (ATR)
- MDGL 14.84
- IVZ 0.76
- MACD
- MDGL -3.14
- IVZ 0.03
- Stochastic Oscillator
- MDGL 22.01
- IVZ 76.96
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (67% of managed assets) and institutional (33%) clients. At the end of April 2025, the firm had $1.840 trillion in assets under management spread among its equity (57% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (11%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).